RecruitingNCT04970056

Pancreatic Cancer Early Detection Consortium

Sponsor

Arbor Research Collaborative for Health

Enrollment

20,000 participants

Start Date

Sep 18, 2020

Study Type

OBSERVATIONAL

Conditions

Pancreatic Ductal Adenocarcinoma Pancreas Cancer Genetic Predisposition Pancreas Cyst

Summary

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study is building a large research database (called PRECEDE) of people at high risk for pancreatic cancer, to enable early detection research and track outcomes over time. **You may be eligible if...** - You have a strong family history of pancreatic cancer (e.g., two or more relatives affected, with specific patterns of relation) and are age 50 or older, OR - You carry certain gene mutations linked to pancreatic cancer risk (such as BRCA1, BRCA2, PALB2, ATM, or Lynch syndrome genes) and have at least one relative with pancreatic cancer, AND you are age 50 or older or within 10 years of the youngest family member's diagnosis - You are at a participating clinical site seeking evaluation for pancreatic cancer risk **You may NOT be eligible if...** - You have previously been diagnosed with pancreatic cancer - You do not meet any of the family history or genetic risk criteria - You are not under surveillance or evaluation at a participating site Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(60)

Mayo Clinic Arizona

Phoenix, Arizona, United States

Honor Health Research Institute

Scottsdale, Arizona, United States

Providence Health and Services

Burbank, California, United States

City of Hope

Duarte, California, United States

UC San Diego Moores Cancer Center

La Jolla, California, United States

Cedars-Sinai Medical Center

Los Angeles, California, United States

UCLA Health

Los Angeles, California, United States

Hoag

Newport Beach, California, United States

UC Irvine Health

Orange, California, United States

UC Davis

Sacramento, California, United States

University of California, San Francisco (UCSF)

San Francisco, California, United States

Yale University

New Haven, Connecticut, United States

Mayo Clinic Jacksonville

Jacksonville, Florida, United States

University of Miami

Miami, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

Emory University Hospital

Atlanta, Georgia, United States

Illinois CancerCare

Bloomington, Illinois, United States

University of Chicago Medicine

Chicago, Illinois, United States

NorthShore University HealthSystem

Evanston, Illinois, United States

University of Kansas Medical Center

Kansas City, Kansas, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Umass Memorial Medical Center

Worcester, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

Beaumont/Corewell Health

Royal Oak, Michigan, United States

University of Nebraska Medical Center

Omaha, Nebraska, United States

Hackensack Meridian Health

Hackensack, New Jersey, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Icahn School of Medicine At Mount Sinai

New York, New York, United States

Columbia University Irving Medical Center

New York, New York, United States

University of Rochester Medical Center

Rochester, New York, United States

White Plains Hospital

White Plains, New York, United States

The Ohio State University

Columbus, Ohio, United States

Oregon Health & Science University

Portland, Oregon, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

University of Pittsburgh Medical Center (Upmc)

Pittsburgh, Pennsylvania, United States

University of Tennessee Graduate School of Medicine

Knoxville, Tennessee, United States

The University of Texas Southwestern Medical Center

Dallas, Texas, United States

MD Anderson Center

Houston, Texas, United States

Huntsman Cancer Institute

Salt Lake City, Utah, United States

Intermountain Health

St. George, Utah, United States

University of Virginia

Charlottesville, Virginia, United States

Inova Schar Cancer Institute

Fairfax, Virginia, United States

VCU Massey Comprehensive Cancer Center

Richmond, Virginia, United States

University of Washington

Seattle, Washington, United States

Epworth HealthCare

Richmond, Victoria, Australia

British Columbia Cancer Agency

Vancouver, British Columbia, Canada

University Health Network

Toronto, Ontario, Canada

McGill University Health Centre

Montreal, Quebec, Canada

Semmelweis University, Institute of Pancreatic Diseases

Budapest, Hungary

Landspitali University Hospital

Reykjavik, Iceland

Sheba Medical Center

Ramat Gan, Israel

Azienda Ospedaliera Universitaria Integrata Verona

Verona, Italy

National Cancer Centre Singapore

Singapore, Singapore

Hospital Clínic de Barcelona

Barcelona, Spain

Hospital Universitari Arnau De Vilanova

Lleida, Spain

Ramón y Cajal University Hospital

Madrid, Spain

National Cheng Kung University Hospital (NCKUH)

Tainan, Taiwan T.o.c., Taiwan

National Taiwan University Hospital

Taipei, Taiwan

University of Liverpool

Liverpool, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04970056

Related Trials

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT0621891418 locations

Vascular Disease Discovery Protocol

NCT035386391 location

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

NCT07076121279 locations

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

NCT0630524712 locations

Lead-212 PSV359 Therapy for Patients With Solid Tumors

NCT067107567 locations